Modifiable barriers for recruitment and retention of older adults participants from underrepresented minorities in alzheimer's disease research
Open accessThe DOI matches its Crossref record; 100 of the 101 references it cites were found in a registry or an index.
Abstract
Clinical Alzheimer’s disease (AD) trials currently face a critical shortfall of thousands of eligible participants, which inflates the duration and cost of the clinical study as well as threatens the scientific merit of promising clinical interventions. This recruitment crisis is further compounded by the fact that underrepresented and marginalized populations—particularly those identifying as a racial or ethnic minority, those with low socioeconomic status, or living in rural areas—have been historically underrepresented in ongoing AD clinical trials despite overwhelming evidence that such populations are at increased risk for developing dementia. As a result of various recruitment barriers, current AD clinical studies frequently reflect a decreasingly representative segment of the US population, which threatens the overall generalizability of these findings. The current narrative review provides an updated examination and critique of common recruitment barriers and potential solutions, as well as a discussion of theoretical approaches that may address barriers disproportionately experienced by underrepresented communities. AD clinical researchers are encouraged to take purposive action aimed at increasing diversity of enrolled AD clinical trial cohorts by actively identifying and quantifying barriers to research participation—especially recruitment barriers and health disparities that disproportionately prevent underrepresented and marginalized populations from participating in research. Furthermore, researchers are encouraged to closely track which individuals who express interest in AD research ultimately enroll in research studies to examine whether AD research participation is appropriately representative of the intended population for whom these new and novel AD interventions are being designed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
EFFECTIVE RECRUITMENT AND RETENTION OF MINORITY RESEARCH PARTICIPANTS
Yancey, A. K., Ortega, A. N., & Kumanyika, S. K. (2006) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.27.021405.102113 · Cited by 1,196 · cited 1×
“questions to staff members [32, 63] stagger and reit-”
Background2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
Increasing Diversity in Clinical Trials: Overcoming Critical Barriers
Clark, L. T., Watkins, L., Piña, I. L., Elmer, M., Akinboboye, O., Gorham, M., Jamerson, B., McCullough, C., Pierre, C., Polis, A. B., et al. (2019) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2018.11.002 · Cited by 731 · cited 5×
“Clinical researchers must also prioritize patient health and safety by frequently monitoring their physical and psychological health and promptly addressing any side-effects experienced by the patient [71].”
BackgroundInfluentialCrocker, J. C., Ricci-Cabello, I., Parker, A., Hirst, J. A., Chant, A., Petit-Zeman, S., Evans, D., & Rees, S. (2018) · BMJ · doi:10.1136/bmj.k4738 · Cited by 624 · cited 1×
“Difficulty in participant recruitment runs the risk of delaying treatment delivery [108] by inflating the duration and cost of the clinical study [6, 108] and has the potential to threaten the external validity of research findings [108].”
BackgroundBabulal, G. M., Quiroz, Y. T., Albensi, B. C., Arenaza‐Urquijo, E., Astell, A. J., Babiloni, C., Bahar‐Fuchs, A., Bell, J., Bowman, G. L., Brickman, A. M., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.009 · Cited by 528 · cited 7×
“Existing research has also demonstrated a difference in AD pathophysiology between African American and Caucasian populations, which may unwittingly result in underdiagnosis of AD among African Americans [91, 92].”
BackgroundInfluentialThe effect of informal care on work and wages
Van Houtven, C. H., Coe, N. B., & Skira, M. M. (2013) · Journal of Health Economics · doi:10.1016/j.jhealeco.2012.10.006 · Cited by 479 · cited 4×
“Caregivers lacking favorable attitudes towards research, fear of potential side-effects, and wish to avoid increasing patient’s burden [9, 10, 66] Provide frequent opportunities to ask clarifying questions [67, 73]; frequent opportunities to discuss risk and benefits of research participation [65]”
BackgroundInfluentialAssessment of Racial Disparities in Biomarkers for Alzheimer Disease
Morris, J. C., Schindler, S. E., McCue, L. M., Moulder, K. L., Benzinger, T. L. S., Cruchaga, C., Fagan, A. M., Grant, E., Gordon, B. A., Holtzman, D. M., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4249 · Cited by 370 · cited 5×
“Community-based providers being unaware of ongoing AD clinical trials [2]; lack of communication between community providers and researchers [74]; absence of formal training for referring providers [65]; time constraints experienced by community-based medical providers [78]; fear of losing patients to medical research…”
BackgroundResultInfluentialMody, L., Miller, D. K., McGloin, J. M., Freeman, M., Marcantonio, E. R., Magaziner, J., & Studenski, S. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.02015.x · Cited by 361 · cited 1×
“Such barriers include 1) medical and/or psychiatric disturbances [2, 31] that may increase heterogeneity in participant response to the treatment protocol and are therefore often identified as exclusionary criteria in ongoing AD research [39], 2) need for a study partner [2], 3) participant burden [40], 4) unique barr…”
Background
Research works printed but not linked: 8
- Institute of Medicine (US) (2012). The Clinical Trials Process, National Academies Press (US).
- Institute of Medicine (2010) Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary.
- Institute of Medicine (US) (2012) Public Engagement and Clinical Trials: New Models and Disruptive Technologies: Workshop Summary, National Academies Press (US), Washington (DC).
- Evelyn B, 2001, J Natl Med Assoc, 93, 18S
- Seitz DP, 2018, Cochrane Database Syst Rev, 2, CD011415
- ManlyJ, MayeuxR (2004) Ethnic differences in dementia and Alzheimer’s disease. In Critical Perspectives on Racial and Ethnic Differences in Health in Late Life , Anderson NB, Bulatao RA, Cohen B, eds. The National Academies Press, pp. 95–142.
- Assistant Secretary for Planning and Evaluation (2014), Racial and Ethnic Disparities in Alzheimer’s Disease: A Literature Review.
- Boise L, 2017, Gerontologist, 57, 719
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Detection and treatment of Alzheimer’s disease in its preclinical stage
Rafii, M. S., & Aisen, P. S. (2023) · Nature Aging · doi:10.1038/s43587-023-00410-4 · Cited by 160
Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials
Langbaum, J. B. S., Zissimopoulos, J., Au, R., Bose, N., Edgar, C. J., Ehrenberg, E., Fillit, H. M., Hill, C. V., Hughes, L., Irizarry, M. C., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12737 · Cited by 131
Representativeness of samples enrolled in Alzheimer's disease research centers
Rentería, M. A., Mobley, T. M., Evangelista, N. D., Medina, L. D., Deters, K., Fox‐Fuller, J. T., Minto, L. R., Avila‐Rieger, J. F., & Bettcher, B. M. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12450 · Cited by 88
Lim, A. C., Barnes, L. L., Weissberger, G. H., Lamar, M., Nguyen, A. L., Fenton, L. E., Herrera, J., & Han, S. D. (2023) · Communications Medicine · doi:10.1038/s43856-023-00333-6 · Cited by 90
Diets to promote healthy brain ageing
Charisis, S., Yannakoulia, M., & Scarmeas, N. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01036-9 · Cited by 70
“…centres, transportation difficulties, language barriers, digital divide such as connectivity and network issues or a lack of comfort with technology, work schedule conflicts (especially for studies requiring frequent appointments and lengthy visits), and low health and research literacy 7,134 .”
InfluentialA New Framework for Dementia Nomenclature
Petersen, R. C., Weıntraub, S., Sabbagh, M. N., Karlawish, J. H., Adler, C. H., Dilworth‐Anderson, P., Frank, L. B., Hummel, C. H., Taylor, A., & Initiative, D. N. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.3664 · Cited by 56
Massett, H. A., Mitchell, A. K., Alley, L., Simoneau, E., Burke, P., Han, S. H., Gallop‐Goodman, G., & McGowan, M. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201463 · Cited by 55
Artificial intelligence for dementia prevention
Newby, D., Orgeta, V., Marshall, C. R., Lourida, I., Albertyn, C. P., Tamburin, S., Raymont, V., Veldsman, M., Koychev, I., Bauermeister, S., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13463 · Cited by 42
Erickson, C. M., Chin, N. A., Ketchum, F. B., Jonaitis, E. M., Zuelsdorff, M. L., Gleason, C. E., & Clark, L. R. (2022) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000490 · Cited by 33
Ketchum, F. B., Erickson, C. M., Chin, N. A., Gleason, C. E., Lambrou, N. H., Benton, S. F., & Clark, L. R. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215521 · Cited by 34
“Proposed solutions 665 have focused on increasing trust and community 666 engagement [39].”
BackgroundRetaining Participants in Longitudinal Studies of Alzheimer’s Disease
Gabel, M. J., Bollinger, R. M., Coble, D. W., Grill, J. D., Edwards, D. F., Lingler, J. H., Chin, E. M., & Stark, S. L. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215710 · Cited by 36
Vascular cognitive impairment and dementia: An early career researcher perspective
Silva, N. C. B. S., Bracko, O., Nelson, A. R., de Oliveira, F. F., Robison, L. S., Shaaban, C. E., Hainsworth, A. H., & Price, B. R. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12310 · Cited by 38
Hackett, K., Xu, S., McKniff, M., Paglia, L., Barnett, I., & Giovannetti, T. (2024) · JMIR Human Factors · doi:10.2196/59974 · Cited by 33
Eliacin, J., Polsinelli, A. J., Epperson, F., Gao, S., Heiden, S. V., Westmoreland, G. R., Richards, R., Richards, M., Campbell, C., Hendrie, H. C., et al. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12399 · Cited by 27
Neuropathology studies of dementia in US persons other than non-Hispanic whites
Nguyen, M.-L., Huie, E. Z., Whitmer, R. A., George, K. M., & Dugger, B. N. (2022) · Free Neuropathology · doi:10.17879/freeneuropathology-2022-3795 · Cited by 24
“The study done by Filshtein et al. utilizing demented cases from the Alzheimer’s Disease Center at UCD, a California based cohort, revealed Latinos/Hispanics had the lowest occurrence of AD clinicopathological diagnosis without the involvement of CVD, including lower frequencies of persons at higher Braak NFT stage co…”
InfluentialThe Importance of Including Underserved Populations in Research
Mehl, K. R., Morain, S. R., & Largent, E. A. (2025) · Pharmaceutical Medicine · doi:10.1007/s40290-025-00562-1 · Cited by 32
“Telemedicine platforms should be designed with accessible user-friendly features, with trial site staff offering technical support, training, and home visits to assist participants as needed [30, 80].”
Perceptions of Research Burden and Retention Among Participants in ADRC Cohorts
Gabel, M. J., Bollinger, R. M., Knox, M. L., Coble, D. W., Grill, J. D., Edwards, D. F., Stark, S. L., & Lingler, J. H. (2022) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000514 · Cited by 19
“1) Sex Female 61 (54) 75 (67) 63 (57) 63 (57) 262 (59) Male 51 (46) 37 (33) 47 (43) 47 (43) 182 (41) Race/ethnicity African American 25 (22) 14 (12) 8 (7) 0 47 (11)”
Barriers and solutions to Alzheimer's disease clinical trial participation for Black Americans
Savold, J., Cole, M. R., & Thorpe, R. J. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12402 · Cited by 26
Yousafi, S., Rangachari, P., & Holland, M. (2024) · Journal of Healthcare Leadership · doi:10.2147/jhl.s488426 · Cited by 19
“18,26,27 These barriers complicate trial enrollment and retention.”
BackgroundRecruiting Persons With Dementia: A Systematic Review of Facilitators, Barriers, and Strategies
Hirt, J., Beer, T., Cavalli, S., Cereghetti, S., Pusterla, E. R. G., & Zeller, A. (2024) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/15333175241276443 · Cited by 23
Neffa-Creech, D., Aggarwal, R., Stowell, C., Menon, U., George, S., Plant, A., & Langbaum, J. B. S. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.67 · Cited by 14
Whitmer, R. A., Baker, L. D., Carrillo, M. C., Snyder, H. M., Cleveland, M. L., Gitelman, D. R., Kivipelto, M., Leng, X., Lovato, L., Papp, K. V., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70351 · Cited by 20
The Coaching for Cognition in Alzheimer's (COCOA) trial: Study design
Roach, J. C., Hara, J., Fridman, D., Lovejoy, J. C., Jade, K., Heim, L., Romansik, R., Swietlikowski, A., Phillips, S., Rapozo, M. K., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12318 · Cited by 14
Bader, I., Groot, C., Tan, H. S., Milongo, J.-M. A., den Haan, J., Verberk, I. M. W., Yong, K. X. X., Orellina, J. A., Campbell, S. R., Wilson, D., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01545-1 · Cited by 12
Kokorelias, K. M., McMurray, J., Chu, C. H., Astell, A. J., Grigorovich, A., Kontos, P., Babineau, J., Bytautas, J., Ahuja, A., & Iaboni, A. (2024) · JMIR Neurotechnology · doi:10.2196/53038 · Cited by 15
“Other barriers to be overcome include cognition [154], physical ability [154], low research literacy [155], lack of cultural competency [155], and speech-and language barriers [154,155].”
Brosch, J. R., Summanwar, D., Fowler, N. R., Hammers, D. B., Perkins, A. J., Higbie, A., Swartzell, K. L., & Willis, D. R. (2025) · BMC Family Practice · doi:10.1186/s12875-025-02977-w · Cited by 13
Assfaw, A. D., Babulal, G. M., Balls‐Berry, J. E., Mozersky, J. T., Moulder, K. L., & Morris, J. C. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70459 · Cited by 14
“26,29,30 Additionally, the pervasive stigma surrounding cognitive decline and mental health issues within specific demographic cohorts further exacerbates reluctance to seek diagnosis or actively participate in research endeavors.”
Dying with dementia in nursing homes: A population‐based study of decedents and their families
Stephens, C. E., Utz, R., Tay, D. L., Iacob, E., Hollingshaus, M., Goodwin, R. M., Farrell, T. W., Bouldin, E. D., Edelman, L. S., Reinke, L. F., et al. (2024) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18770 · Cited by 9
Self- and Informant-Report Cognitive Decline Discordance and Mild Cognitive Impairment Diagnosis
Aaronson, A., Diaz, A., Ashford, M. T., Jin, C., Tank, R., Miller, M. J., Kang, J. M., Manjavong, M., Landavazo, B., Eichenbaum, J., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.5810 · Cited by 9
Pathways to Racial/Ethnic Inequalities in Dementia
Palms, J. D., Sol, K., & Zahodne, L. B. (2025) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-081423-032631 · Cited by 12
Advancing the science of recruitment for Alzheimer’s clinical trials: Challenges and opportunities
Aisen, P. S. S., Peneva, D., Manetas, M.-A., Jacobson, M., Goldman, D. P., Bose, N., Ferrell, P. B., Vu, V., & Raman, R. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100230 · Cited by 9
Gabel, M. J., Denny, A., Llibre‐Guerra, J. J., Morris, J. C., Phillips, J., & Vaidyanathan, A. (2023) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000556 · Cited by 7
Current practices by Alzheimer's Disease Research Centers to remunerate research participants
Gabel, M. J., Bekena, S., O'Meara, M., Denny, A., Solomon, E. D., Moulder, K. L., Morris, J. C., & Mozersky, J. T. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14542 · Cited by 8
“14,20,25 In fact, our recent experimental study found similar increases in willingness to enroll in a hypothetical AD longitudinal cohort study across racial, ethnic, and income groups.”
Brain Health Registry Study Partner Portal: Novel infrastructure for digital, dyadic data collection
Aaronson, A., Ashford, M. T., Jin, C., Bride, J., Decker, J., DeNicola, A., Turner, R., Conti, C., Tank, R., Truran, D., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13492 · Cited by 6
Abramsohn, E., Ornelas, M. D., Borson, S., Frazier, C. R. M., Fuller, C. M., Grana, M., Huang, E. S., Jagai, J. S., Makelarski, J. A., Miller, D. C., et al. (2023) · Trials · doi:10.1186/s13063-023-07697-z · Cited by 12
“Clinical trials with caregivers face particular recruitment and retention challenges including caregiver burden [4–6], lack of caregiver identification in medical records [5, 7], and inconsistent caregiver presence during care recipients’ clinical visits [8].”
BackgroundBader, I., Bader, I., Alves, I. L., García, D. V., Vellas, B. J., Dubois, B., Boada, M., Marquié, M., Altomare, D., Scheltens, P., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01332-4 · Cited by 9
Beyond Alzheimer’s disease—translating biomarker insights across CNS diseases
Brady, L. S., Mahinrad, S., Edelmayer, R. M., Potter, W. Z., Hutten, S. J., Anticevic, A., Taylor‐Burds, C., Winston, C. N., Coetzee, T., Paulsen, J. S., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adr2511 · Cited by 9
Daddato, A. E., Gleason, K. S., Dollar, B., McPhail, T. E. T., Kraus, C. R., & Boxer, R. S. (2024) · The Gerontologist · doi:10.1093/geront/gnad165 · Cited by 6
“This limitation is often encountered in other dementia-related research and highlights the need to employ strategies to reduce potential barriers to recruitment in the future (e.g., language barriers, trust, and burden; Indorewalla et al., 2021).”
BackgroundJacobsen, E. P., Lucas, H. D., Moran, C., Dixon, R. G., & Ganguli, M. (2024) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000618 · Cited by 5
“9,13,18 Since 2006, we have been conducting a longitudinal population study in a cohort of older adults in an under-resourced former steel-manufacturing area of southwestern Pennsylvania, United States.”
MethodArellanes, I., Mirsafian, L., Wang, Y., & Jacobson, M. (2024) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18958 · Cited by 6
Leggins, B., Hart, D. M., Jackson, A. J., LEVENSON, R. W., Windon, C., Merrilees, J. J., & Chiong, W. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01579-5 · Cited by 9
“…or not participating in the trial, informed by common themes of literature discussing incentives and barriers for dementia research participation [9, 14, 19, 20]: the possibility of direct clinical benefit, social responsibilities to participate in research, the possibility of benefiting one’s…”
BackgroundResultWilson, K. P., Marsack‐Topolewski, C. N., Smith, D. M., & Knollman, G. A. (2023) · Family Relations · doi:10.1111/fare.12932 · Cited by 8
Underrepresented and Underserved Populations in Neurological Research
Windon, C., Jackson, A. J., Aguirre, G. A., Tucker, M., Amuiri, A. N., Hill‐Jarrett, T. G., Chen, M. K., Escuedro, S. D. P., Lieu, K., Lopez, L., et al. (2024) · Seminars in Neurology · doi:10.1055/s-0044-1782516 · Cited by 8
Efficacy analysis of multidisciplinary treatment for Wilms tumor in a single center
Ji, F., Wu, C., Li, Y., Zhanghuang, C., Li, J., Li, L., Yang, Z. L., & Yan, B. (2023) · Pediatric Surgery International · doi:10.1007/s00383-023-05408-y · Cited by 7
“Mutations in WT1 [3], TP53 [4], WTX [5], and MYCN [6] genes are associated with the pathogenesis of WT. WT was named after Carl Max Wilhelm Wilms, who first reported pathological character on the disease in 1899 [7].”
Strategic Collaborations and Partnerships in Entrepreneurship
Selvakumar, P., Aradhya, S. G. B., Anute, N., Devi, S. L., Mohit, M., & Vaissnave, V. (2025) · IGI Global eBooks · doi:10.4018/979-8-3693-9836-4.ch009 · Cited by 9
Raelly-Muze, L., Etchison, T., Crouch, A., Eliacin, J., Polsinelli, A. J., Gao, S., Heiden, S. V., Asper, J., Elliott, C., Richards, R., et al. (2025) · Alzheimer s & Dementia Behavior & Socioeconomics of Aging · doi:10.1002/bsa3.70024 · Cited by 6
A qualitative study of recruitment strategies: Perspectives from older adults living with diabetes
Smith, C., Sarteau, A. C., Crampton, C., Noe, V., Qu, X., Busby‐Whitehead, J., Young, L., & Kahkoska, A. R. (2024) · Diabetic Medicine · doi:10.1111/dme.15396 · Cited by 4
“For 5–8 However, it is unknown whether these challenges are similar for qualitative research studies, as they may require less screening and fewer visits than longitudinal clinical studies, and they may be conducted entirely virtually.”
Experiences of participant burden in an Alzheimer's disease research center longitudinal cohort
Gierzynski, T. F., Reader, J. M., Flores, B., Fox‐Fuller, J. T., Gadwa, R., Bhaumik, A., Heidebrink, J. L., Giordani, B., Hampstead, B. M., Bakulski, K. M., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251400787 · Cited by 4
Barriers to Alzheimer Disease Clinical Trial Participation in a Minority Population
Lee, A. Y.-C., Jahansooz, J. R., Guittu, D., Suzuki, R., Pak, L., Ishikawa, K. M., Goo, C., Chen, J. J., Carrazana, E. J., Viereck, J. C., et al. (2023) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0000000000000359 · Cited by 5
“Among minority populations, Asians and Native Hawaiians (NHs) are two of the least researched populations (George et al., 2014; Gilmore-Bykovskyi et al., 2019; Gollin et al., 2005; Indorewalla et al., 2021).”
BackgroundNeuroanatomical and clinical factors predicting future cognitive impairment
Imms, P. E., Chaudhari, N. N., Chowdhury, N. F., Wang, H., Yu, X., Amgalan, A., & Andrei Irimia, A. (2024) · GeroScience · doi:10.1007/s11357-024-01310-0 · Cited by 3
“Racial/ethnic minorities, including Hispanic individuals of any ancestry, are under-represented in AD research [73, 74], including in the NACC dataset.”
Jacklin, K. M., Fergen, J. T., Soderlund, P. D., Cruikshank, K. R., Larson, K., Salisbury, D. L., & Warry, W. (2025) · International Journal of Qualitative Methods · doi:10.1177/16094069251346866 · Cited by 3
Graham, L. A., Ngwa, J. S., Ntekim, O. E., Ogunlana, O., Johnson, S., Nadarajah, S., Fungwe, T. V., Turner, J., Ramirez-Ruiz, M., Khan, J. I., et al. (2022) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-022-01367-7 · Cited by 3
“[21] outlined the barriers to recruitment for older adult participants from underrepresented minorities, noting that the need to undergo repeated diagnostic and neurocognitive evaluations, health insurance issues, lack of adequate transportation to and from the medical facility, and high costs of transportation burden…”
BackgroundRirash, A. F., Franzen, S., Bourdage, R., Kreuk, E., Visser, L. N. C., Babulal, G. M., van den Berg, E., & Papma, J. M. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100557 · Cited by 2
“A lack of representation and diversity within the research staff itself can contribute to mistrust and disconnection with potential participants [60,61,65,82].”
InfluentialSamper‐Ternent, R., Silveira, S. L., Stevens, A. B., Volpi, E., & Naik, A. D. (2023) · Ethnicity & Disease · doi:10.18865/ed.33.2-3.076 · Cited by 6
Runk, A., Butters, M. A., Rosso, A. L., Dubowitz, T., Troxel, W., Rodakowski, J. L., Gary‐Webb, T. L., Haas, A. C., Ghosh‐Dastidar, B., & Weinstein, A. M. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12635 · Cited by 3
“11 Performance-based measures of IADL capacity can assess aspects of capacity different from those assessed by questionnaires, particularly the ability to apply problem-solving skills.”
Bridging the Gap Between Brain Health Guidelines and Real-world Implementation
Correa, D. J., Jordan, J. T., & Said, R. R. (2025) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/cont.0000000000001579 · Cited by 2
Kornder, N., Lindner, N., Ehm, M., Rachor, F., Shan, C. W., Bösner, S., & van der Wardt, V. (2025) · BMC Family Practice · doi:10.1186/s12875-025-02952-5 · Cited by 2
“A key strength is the inclusion of underrepresented groups [43], particularly caregivers with migration backgrounds, allowing for comparative insights into their experiences.”
The primary care brain health navigator: A perspective on implementation
Willis, D. R., Summanwar, D., Fowler, N. R., Brosch, J. R., & Hammers, D. B. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70323 · Cited by 1
“Yet, these high-riskgroupsremainmarkedlyunderrepresentedinclinicaltrials, 39 thereby limiting generalizability.”
Duffner, L. A., Moradi-Bachiller, S., Gove, D., Diaz-Ponce, A. M., Bradshaw, A. C., & Georges, J. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100558 · Cited by 1
“Ongoing difficulties recruiting participants across dementia research fields present a threat to statistical power and the external validity of studies and hampers extrapolation of study results [3].”
Tosserams, A. (2023) · Radboud University Press eBooks · doi:10.54195/9789493296251 · Cited by 1
Balyasnikova, N., & Martin, S. (2024) · Gateways International Journal of Community Research and Engagement · doi:10.5130/ijcre.v17i1.9043 · Cited by 1
Golden, A. G., Williams, C., Yadav, H., Masternak, M. M., Labyak, C. A., Holland, P. J., Arikawa, A. Y., & Jain, S. (2025) · GeroScience · doi:10.1007/s11357-025-01641-6 · Cited by 1
“Among Medicare beneficiaries over the age of 65, 38% had four or more chronic medical illnesses [30].”
Ellingson, K., Degnan, W. J., Nuño, T., Horton, A., Carrasco, C., Rubio, M., Yang, Y., Both, M. D. D., Johnson, M. M., Venkatachalam, H., et al. (2025) · BMJ Public Health · doi:10.1136/bmjph-2024-001721 · Cited by 1
Ellingson, K., Degnan, W. J., Sidhu, A., Lynn, D., Saborio, J. G., Johnson, M. M., Leito, G. M., Carrasco, C., Barnes, C. A., Coon, D. W., et al. (2025) · Gerontology · doi:10.1159/000548419 · Cited by 1
Oh, T. M., Batool, S., Musicha, C., Greene, L., Wheat, H. C., Smith, L., Griffiths, S., Gude, A., Weston, L., Shafi, H., et al. (2025) · BMC Medical Research Methodology · doi:10.1186/s12874-025-02685-0 · Cited by 1
Adeola, H. A., & Robinson, R. A. S. (2025) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.5c00074 · Cited by 1
Eliacin, J., Polsinelli, A. J., Epperson, F., Gao, S., Heiden, S. V., Westmoreland, G. R., Richards, R., Richards, M., Campbell, C., Hendrie, H. C., et al. (2022) · medRxiv · doi:10.1101/2022.09.10.22279803
“Despite interest in AD research [6], they are often hesitant to enroll in intensive AD biomarker studies [7-10].”
BackgroundGrey Matters: The Unique Landscape of Depression Treatment in Older Adults
Yang, X. (2023) · Psychology · doi:10.4236/psych.2023.147064 · Cited by 1
Clark, A. L., Hamlin, A. M., Ortega, N., & Breton, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-820480-1.00181-9
Benson, R. T., Illoh, K., Sankar, C. A., Littlejohn, E. L., Hassani, S., & Akinsanya, J. (2024) · Springer eBooks · doi:10.1007/978-3-031-62727-9_21
Largent, E. A., Grill, J. D., Karlawish, J. H., & Bleakley, A. (2025) · Alzheimer s & Dementia Behavior & Socioeconomics of Aging · doi:10.1002/bsa3.70035 · Cited by 1
Cost-effectiveness of 5-Cog paradigm for individuals with cognitive concerns in primary care
Congivaram, H., Walker, J. M., Ayers, E. I., Chalmer, R., Boustani, M. A., Fowler, N. R., Summanwar, D., Verghese, J., & French, D. D. (2025) · Public Health · doi:10.1016/j.puhe.2025.105963
Recruitment and eligibility in a Phase 1 early Alzheimer's disease trial of Sabirnetug
Moxon, R., Feaster, T., Sethuraman, G., Carroll, A., Gan, S. T., Skljarevski, V., Sundell, K. L., Hitchcock, J. M., & Siemers, E. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70161
Equity, Diversity, and Inclusion in Academic Careers and Research
Orleans‐Foli, S., Linley-Adams, N., & Lewis, L. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009028967.004
Holden, R., Szabo‐Reed, A. N., Watts, A. S., Clutton, J. E., Finley, K., Wolff, S. F., & Burns, J. M. (2025) · Journal of the National Medical Association · doi:10.1016/j.jnma.2025.11.002
“7 Relatedly, obtaining a diverse and representative sample is a highly cited concern 8 with clinical trial recruitment in older adult populations.”
Abramsohn, E., Ornelas, M. D., Soo Borson, B., Frazier, C. R. M., Fuller, C. M., Grana, M., Huang, E. S., Jagai, J. S., Makelarski, J. A., Miller, D. C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24416097
Abramsohn, E., Ornelas, M. D., Soo Borson, B., Frazier, C. R. M., Fuller, C. M., Grana, M., Huang, E. S., Jagai, J. S., Makelarski, J. A., Miller, D. C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24416220
Bader, I., Bader, I., Lopes Alves, I., García, D. V., Vellas, B. J., Dubois, B., Boada, M., Marquié, M., Altomare, D., Scheltens, P., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24494206
Abramsohn, E., Ornelas, M. D., Soo Borson, B., Frazier, C. R. M., Fuller, C. M., Grana, M., Huang, E. S., Jagai, J. S., Makelarski, J. A., Miller, D. C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26629999
Jones, J. D., Valenzuela, Y., Pacheco, M. N., & Nelson, L. A. (2025) · Parkinson s Disease · doi:10.1155/padi/3207928
Sharma, R., Aslam, Y., Faisal, S. B., McAiney, C. A., Chang, F., Sadowski, C. A., Lee, L., Roy, M., Baby, B., Mamdani, M., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341014
Mapping the future of Alzheimer's disease research: Insights from global clinical trial data
Liu, X., Li, Y., Yu, Q., & Su, Y. (2026) · International Psychogeriatrics · doi:10.1016/j.inpsyc.2026.100185
Exclusions affect representativeness of Alzheimer's disease trial participants
Ashford, M. T., Tank, R., Kabeto, M. U., Nosheny, R. L., Weiner, M. W., Weir, D. R., & Langa, K. M. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70191
Fuller, P., Claxton, A., Pocock, H., Williams, S., Claxton, N., Wollam, A., Blackburn, D., Devitt, G., Fearn, S., & Kipps, C. (2026) · medRxiv · doi:10.64898/2026.02.04.26344869
da Rocha, C. G., von Gunten, A., Amoussou, J. R., Fernandes, S., Uittenhove, K. L., Jopp, D. S., Ribeiro, O., & Verloo, H. (2026) · BMC Geriatrics · doi:10.1186/s12877-026-07026-4
Bartley, M. M., Sauver, J. L. S., Schroeder, D. R., Khera, N., & Griffin, J. M. (2026) · Journal of Applied Gerontology · doi:10.1177/07334648261425294
Cognitive screening biases in a secondary prevention Alzheimer's disease clinical trial
Sai, I., Grill, J. D., Younes, K., Winer, J. R., Cody, K. A., Sperling, R. A., Mormino, E. C., & Young, C. B. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71254
Climacosa, F. M. M., Ornos, E. D. B., Diwa, E. R., Guantia, M. G. R., Qureshi, A., Gapaz, N. C. L. L., Dacasin, A. B., Asis, J. L. B., Carampel, A. C., Cruz, A. M. D., et al. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261431318
Undiagnosed dementia in underserved African American populations: Missed opportunities for care
Cohen, G., Mati, M. B., Woodward, O. J., Hepburn, K. W., & Perkins, M. M. (2026) · International Psychogeriatrics · doi:10.1016/j.inpsyc.2026.100208
Orlando, C., Narasimhan, S., Martinez, A., Mata, F., Reasbeck, S., Manrique, C. P., Cardenas‐Iniguez, C., Vicente, I., Chinea, A. R., McCauley, J. L., et al. (2026) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2026.107188
Fuller, P., Claxton, A., Pocock, H., Williams, S. J., Claxton, N., Wollam, A., Blackburn, D. J., Devitt, G., Fearn, S., & Kipps, C. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-118119
Sneed, R. S., Blank, S., Chan, A. C. Y., & Lertzman, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27490-9.00001-4
Metadata
- Authors
- Indorewalla, K. K., O’Connor, M. K., Budson, A. E., Guess (DiTerlizzi), C., & Jackson, J.
- Affiliations
- Edith Nourse Rogers Memorial Veterans Hospital (US)
- Boston University (US)
- Boston University Alzheimer’s Disease Research Center, Department of Neurology, Boston University School of Medicine, Boston, MA, USA
- Corresponding author
- Jackson, Jonathan
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2021-02-17
- Volume
- 80
- Issue
- 3
- Pages
- 927-940
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC8150544
- OpenAlex
- W3130554957
- Cited by
- 93
- References
- 101
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 21 · 2023: 20 · 2022: 10 · 2021: 1
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs (I01 CX001698)
- National Institute on Aging (DP1AG069873, P30AG013846)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- participant recruitment
- MeSH terms
- Alzheimer Disease, Clinical Trials as Topic, Humans, Minority Groups, Patient Selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.